Qvt Financial LP Iovance Biotherapeutics, Inc. Transaction History

Qvt Financial LP

$1.08 Billion
Q1 2024

A detailed history of Qvt Financial LP transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Qvt Financial LP holds 678,564 shares of IOVA stock, worth $4.95 Million. This represents 0.93% of its overall portfolio holdings.

Number of Shares

678,564

Previous 678,564 -0.0%

Holding current value

$4.95 Million

Previous $5.52 Million 82.31%

% of portfolio

0.93%

Previous 0.33%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	BUY	$16.33 - $33.07 $1.45 Million - $2.94 Million	89,048 Added 15.11%	678,564 $17.7 Million
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $1.96 Million - $3.6 Million	68,396 Added 13.12%	589,516 $18.7 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $1.45 Million - $2.61 Million	-51,851 Reduced 9.05%	521,120 $24.2 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $1.99 Million - $2.6 Million	-71,757 Reduced 11.13%	572,971 $18.9 Million
Q1 2020 May 15, 2020	SELL	$19.54 - $38.85 $7.36 Million - $14.6 Million	-376,633 Reduced 36.88%	644,728 $19.3 Million

Q4 2018 Feb 14, 2019	BUY	$7.51 - $11.93 $1.5 Million - $2.39 Million	200,000 Added 24.35%	1,021,361 $8.7 Million
Q2 2018 Aug 14, 2018	SELL	$12.45 - $16.95 $7.35 Million - $10 Million	-590,334 Reduced 41.82%	821,361 $10.5 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $19.5 $2.33 Million - $5.6 Million	287,400 Added 25.56%	1,411,695 $22.5 Million
Q4 2017 Feb 14, 2018	BUY	$6.65 - $9.25 $3.08 Million - $4.29 Million	463,486 Added 70.14%	1,124,295 $8.62 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $2.94 Million - $5.65 Million	660,809	660,809 $5.02 Million

Others Institutions Holding IOVA

# of Institutions

305

Shares Held

221M

Call Options Held

3.05M

Put Options Held

1.6M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.15B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qvt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Qvt Financial LP with notifications on news.

Account